Abstract: Objective To conduct a comprehensive clinical evaluation of the beta-blocker drug arotinolol hydrochloride（arotinolol）, analyze its comprehensive clinical value in essential hypertension and compare with metoprolol tartrate（metoprolol） to provide reference for clinical rational use. Methods In 2021, literature research（meta-analysis）, primary data analysis, pharmacoeconomic model, questionnaire and other methods were used to compare the safety, efficacy, economy and suitability of arotinolol and metoprolol, and the accessibility of arotinolol was analyzed. Results Compared with metoprolol, arotinolol had a higher overall efficiency rate（OR=2.03, 95%CI 1.08 to 3.81, P=0.03）, better diastolic blood pressure reduction mean difference（MD）=3.06（95%CI 0.62 to 5.50） mmHg, P=0.01, relative lower incidence of adverse events and more safety, and it was more cost-effective at the decision thresholds of 1 times the Chinese per capita gross domestic product in 2020（72 447 yuan） incremental cost effectiveness ratio（ICER）=14 519.19 yuan/quality-adjusted life-years（QALYs）. Arotinolol had better taste, good route of administration suitability, and better overall evaluation. The accessibility analysis showed that the price of arotinolol was set in a reasonable range, that long-term use was less likely to lead to household poverty, and the accessibility to healthcare facilities was improving. Conclusion Compared with metoprolol, the third-generation beta-blocker arotinolol has a higher comprehensive clinical value.